Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Disease Attributes » Chronic Disease » Pulmonary Disease, Chronic Obstructive
Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Lung Diseases, Obstructive » Pulmonary Disease, Chronic Obstructive
Description
A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA. MeSH
Hierarchy View
Subtype Terms (3)
Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome
13 drugs (9 approved, 4 experimental)
Bronchitis, Chronic
70 drugs (57 approved, 13 experimental)
Pulmonary Emphysema
9 drugs (4 approved, 5 experimental)
Approved Indicated Drugs (26)
Phase 4 Indicated Drugs (84)
Phase 3 Indicated Drugs (47)
Phase 2 Indicated Drugs (134)
Phase 1 Indicated Drugs (66)
Other Experimental Indicated Drugs (61)
Organization Involved with Phase 4 Indications (185)
Anhui College of Traditional Chinese Medicine
Armed Police General Hospital, P. R. China
Baqiyatallah Medical Sciences University
Blekinge County Council Hospital
Catalan Society of Family Medicine
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Complejo Hospitalario Carlos Haya
Complejo Hospitalario de Especialidades Juan Ramón Jimenez
Dutch Health Care Insurance Board
East West Medical Research Institute
Father Sean O'Sullivan Research Centre
Federal University of Health Science of Porto Alegre
Federation of Associations of Hospital Doctors on Internal Medicine (FADOI) Foundation
Fondo de Investigacion Sanitaria
Fundació Investigació de les Illes Balears
HealthCore-Anthem Research Network
Hellenic Institute for the Study of Sepsis
Hospital of South West Jutland
Hospital Universitario Puerto Real
Hospital Universitario Virgen Macarena
Huazhong University of Science and Technology
Institute of Sera and Vaccines RAS, Moscow
Isala Clinics, Zwolle, The Netherlands
Katholieke Universiteit Leuven
Liaoning Province North Hospital
Los Angeles Biomedical Research Institute
Lustre Pharmaceutical Lab Co., Ltd
Moorgreen Hospital, Southampton
National Health and Medical Research Council, Australia
National Institute for Health Research, United Kingdom
Netherlands Organisation for Scientific Research
People's Liberation Army of China
Rundo International Pharmaceutical Research & Development Co.,Ltd.
Russian Academy of Medical Sciences
Sociedad Española de Neumología y Cirugía Torácica
Spanish Research Center for Respiratory Diseases
Taipei Veteran General hospital
The Korean Academy of Tuberculosis and Respiratory Diseases
Organization Involved with Phase 3 Indications (107)
Ache Laboratorios Farmaceuticos S.A.
Canadian Institutes of Health Research (CIHR)
Cantonal Hospital of St. Gallen
Centers for Medicare and Medicaid Services
Clinical Sciences Center University Hospital Aintree
DongWha Pharmaceutical Company
Federal University of Rio de Janeiro
Health Sciences University Sureyyapasa Chest Diseases and Chest Surgery Hospital
Henan University of Traditional Chinese Medicine
Hopitaux Universitaires Paris Centre
Hospital Son Espases, Palma Mallorca
Liaoning Hospital of Traditional Chinese Medicine
National Cancer Institute (NCI)
National Health Service, United Kingdom
National Heart, Lung, and Blood Institute (NHLBI)
National Science and Technology Development Agency, Thailand
Nova Scotia Health Research Foundation
Oregon Health and Science University
Patient-Centered Outcomes Research Institute
Organization Involved with Phase 2 Indications (117)
Adams Respiratory Therapeutics
Azienda Ospedaliera Antonio Cardarelli
Bangabandhu Sheikh Mujib Medical University
CF Therapeutics Development Network Coordinating Center
Cystic Fibrosis Foundation Therapeutics
Flight Attendant Medical Research Institute
Fondazione Don Carlo Gnocchi Onlus
GeneWorld Co., Ltd., Ho Chi Minh
Icahn School of Medicine at Mount Sinai
Institute of Medicinal Molecular Design, Inc.
Institut fuer Atemwegsforschung GmbH, Wiesbaden, Germany
Institut für Atemwegsforschung GmbH
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
King Edward VII Hospital, Windsor
Medical University of South Carolina
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)
New Horizons Clinical Research
Nguyen Tri Phuong Hospital, Ho Chi Minh city, Viet Nam
Northern Ireland Clinical Trials Unit
Philipps University of Marburg
Pulmonary Associates, Phoenix, AZ
State University of New York, Buffalo
Stichting Astma Bestrijding, The Netherlands
St Joseph's Medical Center, Towson, MD
St. Luke's-Roosevelt Hospital Center
Technology Strategy Board, United Kingdom
Organization Involved with Phase 1 Indications (32)
Organization Involved with Other Experimental Indications (66)
Aristotle University of Thessaloniki
Centre Hospitalier Régional d'Orléans
Chinese Academy of Medical Sciences
European Dairy Association, Brussels
Federal University of Pernambuco
Fundación Neumologica Colombiana
Guangzhou Panyu Central Hospital
Hamilton Health Sciences Corporation
Hoosier Cancer Research Network
Instituto de Molestias Cardiovasculares
Lillehammer Hospital for Rheumatic Diseases
Lillehammer University College
Minnesota Veterans Medical Research and Education Foundation
NATIONAL ASSOCIATION OF GENERAL PRACTITIONERS IN BULGARIA
National Science Centre, Poland
Norwegian School of Sport Sciences
Pulmonary Research Institute Grosshansdorf
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
The Royal Bournemouth Hospital
The Swedish School of Sport and Health Sciences
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
